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INTRODUCTION 
Systematic reviews are a valuable tool to inform healthcare decision-making.(1,2) While a single 
randomised controlled trial (RCT) is insufficient to definitively guide healthcare decisions, a 
systematic review synthesising multiple RCTs can overcome this limitation. The results of rigorous 
systematic reviews possess wide-ranging applicability to numerous stakeholders within the evidence-
based medicine ‘ecosystem’. Clinicians consult systematic reviews to inform their clinical 
decisions.(3) Researchers rely on systematic reviews to identify knowledge gaps in existing 
literature.(4) Health policymakers use systematic review evidence to inform practice guidelines and 
legislation.(5,6) Journal editors often prioritize systematic reviews for their impact on readership 
attention and journal metrics.(7) Finally, patients are empowered by systematic reviews that assess the 
beneficial and harmful patient-important outcomes of available management strategies.(8) Systematic 
review authors have an important responsibility to ensure their findings provide the most credible 
results possible. 
  
The biomedical literature expands by twenty-two systematic reviews daily,(9) with no evidence that 
production is waning. More systematic reviews are desirable if they identify and inform important 
research questions that improve patient care.(10) However, production of this magnitude is 
problematic when systematic reviews offer “extensive redundancy, little value, misleading claims, 
and/or vested interests.”(11) As we outlined in Part 1, bias is a systematic deviation from the truth in 
the results of a research study, due to limitations in study design, conduct, or analysis.(2) Deviations 
may either over- or under-estimate a study’s true findings depending of the type and magnitude of 
bias. As the results of a systematic review are only as valid as the studies it includes, pooling biased 
studies can compromise the credibility of systematic review findings when no assessment, or a poor 
assessment, of risk of bias is performed.(3,12)  
 
Inadequate study design, conduct, or analysis, devalue the credibility of biomedical research and the 
competence of clinicians to care for patients.(13) Comprehensively assessing risk of bias instead of 
study quality – using a domain-based risk of bias assessment instead of a quality scale or checklist – is 
the best method to avoid overlooking biased evidence that propagates misleading systematic review 
findings. This two-part education primer focuses on critical assessments as a source of misleading 
systematic review conclusions. In part one, we introduced risk of bias as the perceived risk that the 
results of a research study deviate from the truth. In part two, we: 
1. Evaluate the prevalence of and methods used to critically assess study findings included in 
systematic reviews published in BJSM.  
2. Perform a risk of bias assessment on a sample of RCTs in a systematic review, to compare 
risk of bias assessment findings with study quality assessment findings. 
3. Illustrate the impact that different assessment tools have on risk of bias assessment findings, 
and ultimately, systematic review findings. 
4. Provide recommendations to systematic review authors who are planning a risk of bias 
assessment.  
  
EMPIRICAL EVIDENCE FROM SPORT AND EXERCISE MEDICINE 
Sport and Exercise Medicine (SEM) research is vulnerable to bias across many empirical study 
designs.(14,15) The characteristics of risk of bias assessments in SEM systematic reviews are 
unknown. Evaluating how risk of bias assessments are conducted is necessary to determine whether 
risk of bias is adequately assessed across SEM research. We performed a cross-sectional study to 
determine the methods used to critically appraise the credibility of original study findings in 
systematic reviews published in BJSM. 
  
Methods 
We searched the BJSM journal archive (http://bjsm.bmj.com/content/by/year) on May 11th, 2017 to 
identify systematic reviews published since January 1st, 2016. Systematic reviews performing a 
descriptive synthesis or meta-analysis, and published in BJSM between 1st January 2016 and 10th May 
2017, were eligible for inclusion.  
 Two authors (FCB & ED) independently screened titles and abstracts to identify systematic reviews. 
Review article types that did not systematically identify and select eligible studies, and synthesise 
relevant study content (e.g., narrative/critical reviews, PEDro syntheses, consensus statements and 
practice guidelines) were excluded. A third author (CLA or MW) arbitrated disagreements. 
Descriptive characteristics of each systematic review were independently abstracted by two authors 
(FCB & ED) using a pre-defined data extraction template (Table 1).  
Table 1. Critical assessment tool and method variables extracted from BJSM systematic reviews  
# Outcome variable extracted Levels of each outcome variable 
1 Critical assessment tool implemented Yes, no, unclear. 
2 Critical assessment tool name Cochrane Risk of Bias Tool, PEDro, etc. 
3 Critical assessment tool type Standard tool: Systematic review authors used a published tool. 
Adapted tool: Systematic review authors modified a published tool for their use.  
Custom tool: Systematic review authors created a new tool to critically appraise 
included studies.  
4 Critical assessment tool format Scale: Multiple tool items were assigned a quantitative value and combined to 
generate a single numeric summary score. 
Checklist: Tool items possessed a descriptive, discrete outcome (e.g., “yes”, “no”, 
“maybe”) without an assigned numeric value.  
Domain-based tool: Separate assessments were made for different risk of bias 
domains, with subjective judgements of “low risk”, “unclear”, and “high risk” 
determined by established criteria.  
5 Ranking system prevalence and type, 
if applicable 
Summary score: Tool items were summed to generate a single numeric value. 
Threshold summary score: Tool items were summed to generate a single numeric 
value with arbitrary cut-off values used to classify studies as being at ‘low’, 
‘moderate’/ ‘unclear’, or ‘high’ quality/risk of bias.  
6 Risk of bias assessment method Domain-based assessment 
Separate assessments for different subjective and objective outcome types 
7 Method used to incorporate critical 
assessment findings into systematic 
review findings 
Sensitivity analysis  
Meta-regression 
Exclude studies at high or unclear risk of bias (or moderate or low quality) from the 
synthesis 
Narrative discussion (with minimal evidence for incorporation deemed acceptable) 
No attempt to incorporate risk of bias assessment findings into systematic review 
findings 
 
 
One author (FCB) performed pilot data extraction on a subsample of systematic reviews prior to full 
data extraction. Two authors (FCB & ED) independently extracted data from each included 
systematic review. A third author (CLA or MW) arbitrated disagreements. Data are presented as 
absolute frequencies (n) and as a proportion (%) of the sample of systematic reviews. 
 
Results 
We included 66 systematic reviews.  
• Sixty-five (99%) systematic reviews reported a critical assessment of included studies. Table 
2 lists the characteristics of critical assessment tools used. Critical assessment tools used in 
systematic reviews are included in Supplementary Table 2. 
• Forty-two (65%) systematic reviews used a standard tool, 14 (21%) used an adapted tool, and 
9 (14%) used a custom tool.  
• Eighteen (28%) systematic reviews used a checklist to critically assess included studies, 38 
(58%) used a scale, and 9 (14%) used a domain-based assessment tool.  
• Fifty (77%) systematic reviews used a ranking system that ranked studies based on critical 
assessment findings. Nineteen (38% of 50) systematic reviews ranked studies based on a 
summary score of methodological study quality. Thirty-one (62% of 50) ranked studies using 
a threshold summary score to classify studies in categories of “high”, “moderate”, or “low 
quality”. 
• Of sixty-five systematic reviews that performed a critical assessment of included studies, 11 
(17%) performed a risk of bias assessment for separate outcomes. Three (5%) performed a 
domain-based risk of bias assessment for separate outcomes; 10 (15%) performed domain-
level risk of bias assessments but not for separate outcomes. Forty-seven (72%) systematic 
revies presented risk of bias assessment findings for each tool item but not for individual risk 
of bias domains or for separate outcomes.  
• Two systematic reviews (3%) performed a meta-regression to examine the quantitative 
influence of risk of bias or study quality of each included study on individual study effect 
size. Ten (15%) performed a sensitivity analysis to compare the effect estimates of studies at 
‘high’ and ‘unclear’ risk of bias to all included studies. One systematic review (2%) excluded 
studies at ‘high’ and ‘unclear’ risk of bias from the synthesis to restrict their evidence 
synthesis to studies at low risk of bias. Forty-three (66%) narratively discussed risk of bias 
assessment findings in the context of systematic review findings, and 9 systematic reviews 
(14%) did not incorporate risk of bias assessment findings into review findings.   
 
Table 2. Prevalence & methodological features of critical 
assessment performed in systematic reviews published in BJSM. 
 
Data items Reviews 
k (%) 
Critical assessment performed in systematic review 65 (99%) 
Critical assessment tool type  
Standard tool  42 (65%) 
Adapted tool  14 (21%) 
Custom tool  9 (14%) 
Critical assessment tool format  
Checklist 18 (28%) 
Scale 38 (58%) 
Domain-based 9 (14%) 
Ranking system 50 (77%) 
Simple summary score 19 (38%) 
Cut-off threshold score  31 (62%) 
Separate critical assessments for each outcome  
Yes 11 (17%) 
No 54 (83%) 
Domain-based assessment across outcomes  
Yes 10 (15%) 
No 55 (85%) 
Critical assessment for each tool item  
Yes 47 (72%) 
No 18 (28%) 
Methods to incorporate risk of bias assessment findings into review findings 
Meta-regression (quantitative) 2 (3%) 
Sensitivity analysis (quantitative) 10 (15%) 
Excluded studies at high or unclear risk of bias (or moderate or low quality) 
(qualitative) 
1 (2%) 
Qualitative description (i.e. narrative discussion)     43 (66%) 
No attempt to incorporate risk of bias assessment findings into review findings  9 (14%) 
CRITICAL RE-ASSESSMENT USING A RISK OF BIAS ASSESSMENT INSTEAD 
OF AN ASSESSMENT OF STUDY QUALITY 
Features of risk of bias assessments including the terminology, assessment tool and method, and 
incorporation method used, influence risk of bias assessment findings. In this section, we present a 
worked example where we re-assess the risk of bias of RCTs in one BJSM systematic review.(16) By 
assessing the risk of bias in RCTs, we illustrate the impact that different critical assessment tools can 
have on risk of bias assessment findings, and ultimately, systematic review findings. 
 
Methods of risk of bias assessment 
We used pre-specified inclusion criteria to identify a systematic review (from our original group of 
65) that included intervention studies and intended to assess risk of bias, but evaluated features other 
than risk of bias (Eligibility criteria – supplementary file 1). Our eligibility criteria identified a 
systematic review (16) that investigated the efficacy of therapeutic interventions to improve patient-
reported function in participants with chronic ankle instability (CAI). This systematic review included 
17 original research studies: 11 RCTs, 1 cohort study, 2 case-control studies, and 3 case-series. For 
the purpose of this education review, we re-assessed only the 11 RCTs included in this systematic 
review.(16) An author of the current study (ED) contacted a member of the systematic review team to 
articulate the current study’s aims and to obtain the review authors’ permission to perform a risk of 
bias assessment of RCTs included in their systematic review. The lead and supervising authors of this 
systematic review(16) also provide a commentary on the current study’s findings in the context of 
their systematic review findings (see Kosik & Gribble). 
 
We assessed the risk of bias in outcomes of patient-reported function (activities of daily living (ADL) 
and sports subscales) in eleven RCTs(16) using the Cochrane Risk of Bias tool 2 (RoB2). RoB2 is the 
revised, second edition of the Cochrane Risk of Bias tool for RCTs.(17,18) RoB2 is an outcome-
focused, domain-based tool that assesses the risk of bias of outcomes in individually-randomized, 
parallel-group trials, randomized cross-over trials, and cluster-randomized controlled trials.(18) 
 
RoB2 features five risk of bias domains for individually-randomized, parallel-group trials:  
1. Bias arising from the randomization process;  
2. Bias due to deviations from intended interventions;  
3. Bias due to missing outcome data;  
4. Bias in measurement of the outcome,  
5. Bias in selection of the reported results.  
 
Responses to the RoB2 signaling questions are mapped using a decision algorithm to determine each 
risk of bias domain judgement.(18) Finally, an overall risk of bias judgement is made for each 
assessed outcome, in each trial, based on the domain-level assessment. A study outcome is judged as 
‘low risk’ when all domains are judged to be at low risk of bias. A study outcome is determined to 
have ‘some concerns’ of bias when one or more domains are judged to be at ‘some concerns’ of bias. 
A study outcome is judged as ‘high risk’ of bias when at least one domain is judged to be at ‘high 
risk’ of bias, or when multiple domains have ‘some concerns’. Multiple domains at ‘some concerns’ 
of bias raise the likelihood of distortion of the treatment effect (i.e., a high overall risk of bias). Strong 
meta-epidemiological evidence supports the content of risk of bias domains included in RoB2.(19)  
 
Two independent assessors (FCB & ED) re-assessed the risk of bias of the eleven RCTs using the 
revised version of RoB2 from October 9th, 2018 (http://www.riskofbias.info).(18) Assessors resolved 
initial disagreement via discussion. A third, independent assessor (MW & RE) arbitrated any 
persisting disagreements. Assessor were not blind to the findings of the Downs & Black quality 
assessment performed by Kosik et al.(16) 
 
Results of study quality assessment and risk of bias assessments 
Kosik et al.(16) performed an intended risk of bias assessment using the Downs and Black Checklist. 
The Downs and Black Checklist is a quality assessment scale developed to evaluate the 
methodological quality of randomized and non-randomized trials.(20) The checklist comprises 27 
items across 4 subscales including: completeness of reporting (9 items); internal validity (13 items); 
precision (1 item), and; external validity (3 items). The Downs and Black Checklist assigns numeric 
values to item responses (‘Yes’ = 1; ‘No’ = 0; ‘Unable to determine’ = 0). Each item score is 
summed; higher scale summary scores indicate superior study quality. The Downs and Black 
Checklist considers the methodological quality of each study irrespective of the number and type of 
outcomes assessed within each study. 
 Risk of bias reassessment: Bias arising from the randomization process 
Eight trials (73%) had outcomes at ‘some concerns’ of bias arising from the randomisation process. 
This was due to improper or unclear methods of sequence generation, allocation concealment, or due 
to imbalances in group baseline demographic characteristics. Outcomes in 2 RCTs (18%) had ‘high’ 
risk of bias arising from the randomisation process. One RCT (9%) had an outcome at ‘low’ risk of 
bias.  
 
Risk of bias reassessment: Bias due to deviations from intended interventions 
Seven RCTs (64%) had outcomes at ‘high’ risk of bias due to deviations from intended interventions 
with specific interest in lack of adherence to the intervention. Two trials (18%) had ‘some concerns’ 
of bias and two trials (18%) had ‘low’ risk of bias. 
 
Risk of bias reassessment: Bias due to missing outcome data 
Two RCTs (18%) had outcomes at ‘high’ risk of bias due to missing outcome data. Nine trials (82%) 
had outcomes that were at ‘low’ risk of bias due to little, or no, missing outcome data.  
 
Risk of bias reassessment: Bias in measurement of the outcome 
Nine RCTs (73%) had outcomes at ‘high’ risk of bias, predominantly due to a lack of participant 
blinding. Trial participants were outcome assessors due the use of patient-reported outcome measures. 
Two trials (18%) were at ‘low’ risk of bias and 1 trial (9%) was at ‘some concerns’ of bias in 
measurement of the outcome.  
 
Risk of bias reassessment: Bias in selection of the reported results 
One RCT (9%) was at ‘high’ risk of bias in selection of the reported results. Ten trials (91%) had 
outcomes at ‘some concerns’ of bias. ‘Some concerns’ of bias were due to no available pre-specified 
trial protocol or analysis plan, and the possibility for many statistical analyses, other than that reported 
in the results of each trial, to be performed. 
 Risk of bias reassessment: Overall risk of bias for patient-reported function 
All RCTs (k = 11; 100%) were at ‘high’ overall risk of bias for all intervention comparisons and 
follow-up assessment time-points. RCTs were at ‘high’ overall risk of bias due to the presence of at 
least one risk of bias domain at ‘high’ risk of bias or multiple risk of bias domains at ‘some concerns’ 
of bias (Table 3).(21–31). 
 
Study quality 
The assessment of study quality (using the Downs and Black checklist) produced a mean scale 
summary score of 21 out of 31 (minimum-maximum = 11-24) across eleven RCTs.(16) Eight RCTs 
were judged by Kosik et al. as high quality and 3 RCTs were judged by Kosik et al. as moderate 
quality. 
 
Summary  
Using the Downs and Black checklist, the majority of included RCTs (8/11) were judged to be high-
quality trials. Kosik et al. interpreted study quality assessment findings to provide moderate-to-high 
quality evidence for therapeutic interventions improving patient-reported function in individuals with 
chronic ankle instability (CAI). Using ROB2 on the same sample of RCTs, all trials were judged to be 
at ‘high’ overall risk of bias. Our interpretation is that the current evidence for therapeutic 
interventions in individuals with CAI is likely prone to bias-limiting conclusions. 
 
 
 
 
 
Table 3. Overall and domain-level risk of bias judgements for each review outcome,  
intervention comparisons, and follow-up assessments timepoints. 
Study Outcome Intervention 
comparison 
Follow-up 
assessment 
time-points 
Bias arising due to 
the randomization 
process 
Bias due to deviation from 
intended interventions 
(adhering to the intervention) 
Missing 
outcome 
data 
Bias due to 
measurement 
of the outcome 
Bias due to 
selection of the 
reported result 
OVERALL 
RISK OF BIAS 
JUDGEMENT 
Wright et al., 
2017. 
FAAM-ADL 
FAAM-Sport 
Wobble board balance training vs. 
ankle strengthen resistance tubing 
Day intervention 
ceased 
Some Concerns Some Concerns Low Risk Some Concerns Some Concerns High Risk 
Donovan et al., 
2016. 
FAAM-ADL 
FAAM-Sport 
Exercise rehabilitation using 
destabilization device vs. exercise 
rehabilitation using no 
destabilization device 
48-hour  
follow-up 
Some Concerns High Risk Low Risk High Risk Some Concerns 
 
High Risk 
McKeon & 
Wikstrom 2016 
FAAM-ADL 
FAAM-Sport 
Ankle joint mobilization vs. plantar 
massage vs.  
triceps surae stretching  
vs. control  
72-hour  
follow-up 
Low Risk High Risk Low Risk High Risk Some Concerns 
 
High Risk 
4-week  
follow-up 
Low Risk High Risk Low Risk High Risk Some Concerns 
 
High Risk 
Cruz-Diaz et 
al., 
2015. DR.  
CAIT Group 1: Intervention 
Group 2: Sham intervention 
Group 3: Control group 
3-week  
follow-up 
Some Concerns High Risk Low Risk Low Risk Some Concerns High Risk 
6-month 
follow-up 
Some Concerns High Risk Low Risk Low Risk Some Concerns High Risk 
Cruz-Diaz et 
al., 2015. IJSM. 
CAIT Comprehensive exercise program 
vs. general lower body strength 
program 
Day intervention 
ceased 
Some Concerns Low Risk Low Risk High Risk Some Concerns High Risk 
Lubbe et al., 
2015. 
FADI-ADL Manual therapy + rehabilitation vs. 
rehabilitation alone 
Day intervention 
ceased 
Some Concerns High Risk Low Risk High Risk High Risk High Risk 
Salom-Moreno 
et al., 2015. 
FAAM-ADL 
FAAM-Sport 
TrP-DN + strength/ 
proprioceptive training 
vs. strength/proprioceptive training 
4-week  
follow-up 
Some Concerns Some Concerns Low Risk High Risk Some Concerns High Risk 
Collins et al., 
2014. 
FAAM-ADL 
FAAM-Sport 
Strain counter-strain vs. sham 
strain counter-strain 
Day intervention 
ceased 
High Risk Low Risk Low Risk Low Risk Some Concerns High Risk 
Beazell et al., 
2012. 
FAAM-Sport Group 1: Proximal tibio-fibular 
manipulation  
vs. 
Group 2: Distal tibio-fibular 
manipulation  
vs. 
Group 3: Control group –  
no intervention 
Intervention Day 
1 
Some Concerns High Risk Low Risk High Risk Some Concerns High Risk 
Day 7 of 
intervention 
Some Concerns High Risk Low Risk High Risk Some Concerns High Risk 
Day 14 
of intervention 
Some Concerns High Risk Low Risk High Risk Some Concerns High Risk 
Day 21 
of intervention 
Some Concerns High Risk Low Risk High Risk Some Concerns High Risk 
Schaefer & 
Sandrey (2012). 
FAAM-ADL 
FAAM-Sport 
GISTM + balance training vs. 
Sham GISTM + balance training 
vs. balance training 
Day intervention 
ceased 
High Risk High Risk High Risk High Risk Some Concerns High Risk 
McKeon (2008) FAAM-ADL 
FAAM-Sport 
Balance training vs. control group 4-week  
follow-up 
Some Concerns High Risk High Risk High Risk Some Concerns High Risk 
Abbreviations: IJSM = International Journal of Sports Medicine; DR = Disability & Rehabilitation; FAAM-
ADL = Foot & Ankle Ability Measure – Activities of Daily Living Subscale; FAAM-Sport = Foot & Ankle 
Ability Measure – Sports Subscale; CAIT = Cumberland Ankle Instability Tool; TrP-DN = TriggerPoint – Dry 
Needling; GISTM = Graston Instrument-assisted Soft Tissue Mobilization 
IMPLICATIONS & RECOMMENDATIONS 
We found a high prevalence of critical assessments among systematic reviews published in BJSM. 
Risk of bias assessments were infrequently performed in systematic reviews published in BJSM. 
Many systematic reviews assessed study quality instead of risk of bias, which impairs accurate 
inferences about the credibility of study outcomes.(2,32,33)  
 
Performing an assessment of study quality instead of a risk of bias assessment may lead to invalid 
systematic review findings, conclusions, and recommendations. The quality assessment of 11 RCTs in 
our worked example produced a mean summary score of 20.5 out of 31 (66%; minimum-maximum = 
11–24), indicating moderate-to-high quality evidence.(16) Kosik and colleagues did not categorize 
scale summary scores into equal tertiles.(16) If categorized into equal tertiles of low (1-10), moderate 
(11-20), and high quality (21-31), 8 RCTs were of high quality, 3 RCTs were of moderate quality, and 
no RCT was judged to be of low quality (Table 4). However, using a risk of bias assessment, all RCTs 
were judged to be at ‘high’ overall risk of bias using RoB2 (Table 4).  
 
Domains should dominate risk of bias assessments 
Despite empirical evidence to support domain-based risk of bias assessment tools, approximately one-
third of SEM systematic reviews included in our sample did not use an empirically-supported tool. 
Only 14% performed a domain-based risk of bias assessment while most used scales or checklists. 
This estimate of 14% in our sample of SEM systematic reviews is lower than in biomedicine where 
41% of non-Cochrane systematic reviews used a domain-level risk of bias assessment tool.(9)  
 
Scale summary scores often lack meaning and omit valuable information about specific study 
limitations in individual studies.(34,35) For example, summary scores presented in the systematic 
review example ranged from 11/31 to 24/31 (Table 4).(16) Reporting only one numeric value 
provides insufficient detail to highlight specific limitations in trial design, conduct, or analysis that 
threaten trial validity.(36,37)  
 
Using RoB2, in every RCT we identified at least one domain at ‘high’ risk of bias or multiple 
domains at ‘some concerns’ of bias for each assessed outcome. Due to available evidence on the 
relationships between various risk of bias domains and distorted effect estimates,(9,38,39) the use of 
an established domain-based tool enables a deeper understanding about the likely direction and size of 
trial effect estimates associated with bias. Our risk of bias assessment findings highlight that despite 
high trial quality,(16) all RCTs were at ‘high’ overall risk of bias. This renders the current evidence of 
therapeutic interventions for CAI prone to bias-limiting conclusions about patient-reported function. 
  
Focus on outcomes, not trials 
Systematic review authors should perform separate risk of bias assessments for subjective and 
objective outcomes rather than assess all review outcomes simultaneously using the same risk of bias 
assessment.(2) Study limitations can distort separate outcomes differently,(9,40) necessitating 
separate risk of bias assessments for different outcome types. For example, a subjective outcome, such 
as self-reported pain, is more likely to be over-estimated when a patient is aware of their allocation to 
a specific intervention group, (due to lack of patient blinding) than if they were not aware of their 
group allocation.(9) Conversely, a patient’s awareness of their allocation to a therapeutic intervention 
group is less likely to influence an objective outcome such as re-injury. 
 
Only half of systematic reviews across biomedicine, and 17% in our sample, performed separate risk 
of bias assessments for subjective and objective outcomes.(41) Kosik et al. (16) reported patient-
reported function (activities of daily living and sporting activities). Due to the subjective nature of 
patient-reported outcomes, the effect of study limitations due to deviation from intended interventions 
(e.g., lack of patient blinding) may overestimate differences between intervention and control groups. 
Table 4. A tabular comparison of trial quality, using Down & Black Quality Checklist, and risk of bias, using RoB 2.0. 
 
Lead-author 
(Year) 
Outcome 
measure 
Downs & Black Quality Checklist Cochrane RoB Tool 2.0  
Summary Score Quality Category Overall Risk of Bias Judgement 
Wright et al., 2017. FAAM-ADL 
FAAM-Sport 
CAIT (ADL) 
22 High quality High Risk 
Donovan et al., 
2016. 
FAAM-ADL 
FAAM-Sport 
22 High quality High Risk 
McKeon & 
Wikstrom 2016 
FAAM-ADL 
FAAM-Sport 
23 High quality High Risk 
Cruz-Diaz et al., 
2015. DR.  
CAIT (ADL) 21 High quality High Risk 
Cruz-Diaz et al., 
2015. IJSM. 
CAIT (ADL) 21 High quality High Risk 
Lubbe et al., 2015. FADI-ADL 23 High quality High Risk 
Salom-Moreno et 
al., 2015. 
FAAM-ADL 
FAAM-Sport 
22 High quality High Risk 
Collins et al., 2014. FAAM-ADL 
FAAM-Sport 
11 Moderate quality High Risk 
Beazell et al., 2012. FAAM-Sport 24 High quality High Risk 
Schaefer & 
Sandrey (2012) 
FAAM-ADL 
FAAM-Sport 
20 Moderate quality High Risk 
McKeon (2008) FADI-ADL  
FADI-Sport 
17 Moderate quality High Risk 
OVERALL BODY 
OF EVIDENCE 
Patient-reported 
function 
Mean = 21 
Min – Max = 11-24 
HIGH QUALITY HIGH RISK 
 
Abbreviations: IJSM = International Journal of Sports Medicine; DR = Disability & Rehabilitation; FAAM-ADL = Foot & Ankle Ability Measure – Activities of Daily Living 
Subscale; FAAM-Sport = Foot & Ankle Ability Measure – Sports Subscale; CAIT = Cumberland Ankle Instability Tool.  
Cut-off scores to differentiate quality categories: Low quality = 1-10; Moderate quality = 11-20; High quality = 21-31. 
 
 
 
Incorporating risk of bias assessment findings into systematic review findings 
Incorporating risk of bias assessment findings into systematic review findings allows an interpretation 
of over- or under-estimated study outcomes, to avoid misleading conclusions. High numbers of 
studies at ‘some concerns’ or ‘high’ risk of bias necessitate a more cautious interpretation of review 
findings. Two thirds of systematic reviews in our sample presented a qualitative description of risk of 
bias assessment findings. However, these systematic reviews did not estimate the likely impact of bias 
on systematic review outcomes.(19) Approximately one in five systematic reviews used quantitative 
methods to adjust the review effect estimate based on the risk of bias present in included studies 
(Table 2).(2,41–44) 
 
Table 5– Incorporating risk of bias assessment findings into review findings 
Method Explanation 
Quantitatively incorporating risk 
of bias assessment findings when 
undertaking a meta-analysis 
Sensitivity analyses can evaluate whether effect estimates change if only studies at ‘low’ risk of 
bias are included in meta-analysis compared to all included studies.(34) 
Meta-regression is a secondary analysis that assesses the quantitative influence of overall risk of 
bias judgements (e.g., ‘low’, ‘some concerns’, or ‘high’) of studies on the meta-analytic effect 
estimates.(43)  
Qualitative description 
(descriptive information when 
there is no meta-analysis) 
 
 
A detailed discussion can speculate about the extent to which included studies, at ‘some 
concerns’ or at ‘high’ risk of bias, may under-estimate or over-estimate review findings 
compared to studies at ‘low’ risk of bias.(19)  
Excluding studies at a pre-specified risk of bias judgement from the evidence synthesis offers an 
addition to a simple descriptive synthesis. For example, systematic review authors might decide 
to include only studies at ‘low’ risk in specific bias domains. By excluding studies at ‘some 
concerns’ and ‘high’ risk of bias from the synthesis, review authors may plausibly reduce the 
extent to which review findings are exposed to biased study-level data. Another approach to 
account for risk of bias is to visually present study findings according to risk of bias assessment 
findings.  
 
 
How believable is the review effect estimate if bias is present? 
In the RCTs descriptively synthesized by Kosik et al.,(16) small, non-significant between-group 
differences could represent an under-estimate due to bias that under-represents that true magnitude of 
an intervention’s effect. The true difference between groups may actually be larger, but we cannot be 
certain because of high risk of bias across many domains. Therapeutic interventions may be more or 
less effective than concluded in the systematic review.(16) Applying an evidence-grading tool to 
‘high’ overall risk of bias judgments in this systematic review lowers the quality of evidence and 
strength of recommendation for balance training and multimodal treatment (Strength of 
Recommendation Taxonomy (SORT) used by Kosik et al.(16)). 
 
In the presence of inarguable demonstrations that substantiate why “most published research findings 
are false”,(45) researchers must be able to identify study outcomes at ‘some concerns’ or ‘high risk’ 
of bias. To accomplish this, researchers need to perform separate domain-based risk of bias 
assessments (for separate subjective and objective outcome) that evaluate potential threats to a study’s 
internal validity. In table 6, we present recommendations for systematic review authors and editorial 
team members to inform the conduct of a valid risk of bias assessment. These recommendations 
reflect a blend of information from contemporary texts in evidence synthesis methods, peer-reviewed 
meta-research, editorial and evidence synthesis experience, and the findings of our methodological 
study.  
 
Table 6 – Guidance checklist for systematic review authors, peer-reviewers, and editorial  
team members when performing and interpreting risk of bias assessments: 
1) Assess risk of bias:  
Avoid assessing study quality in place of risk of bias. Use a rigorously-developed, study design-specific risk of bias tool such 
as RoB2 (for randomized intervention trials), ROBINS-I (for non-randomized interventions studies), ROBIS (for systematic 
reviews), PROBAST (for prediction modelling studies), QUIPS-II (for prognostic studies), or QUADAS-II (for diagnostic 
accuracy studies). 
2) Use a risk of bias assessment tool in its original form:  
Do not modify risk of bias tools by adding new items or omitting existing items that might deem to be relevant or irrelevant to 
the assessment of risk of bias. Modifying a standard risk of bias assessment tool can negatively impact on the sensitivity of the 
risk of bias assessment, by potentially including an item that does not address risk of bias. Systematic review authors should 
not develop and/or use their own critical assessment tool to assess bias. 
3) Evaluate and present risk of bias using a domain-level risk of bias assessment: 
Domain-level risk of bias assessments consider the effect of risk of bias domains on study outcomes rather than one summary 
score. Individual risk of bias domains contribute differently to the extent that study limitations may distort study results.  
4) Avoid using scales and checklists to assess risk of bias: 
Scales and checklists frequently generate summary scores by using one numeric value, which omits information about diverse 
sources of bias. Judging the risk of bias for a particular outcome based on individual domains is recommended because 
several domains at ‘some concerns’ or ‘high’ risk of bias raise the suspicion that an effect estimate may be distorted. 
5) Avoid cut-off thresholds that categorise studies based on risk of bias or study quality: 
Cut-off thresholds that dichotomise or categorise ordinal scales of study quality into nominal groups (of ‘high’, ‘moderate’, or 
‘low’ study quality) omits valuable information about methodological differences between studies. There is no evidence to 
support the numeric ranking of studies based on overall study quality, particularly when independent items contribute towards 
the overall quality score of a study. 
5) Assess risk of bias separately for different outcomes:  
Subjective outcomes, such as pain, are more strongly influenced by participants’ and outcome assessors’ awareness of 
methodological phenomena such as knowledge of group assignment. An objective outcome, such as death, is more resistant to 
the influence of bias. 
6) Incorporate risk of bias assessment findings into systematic review findings using quantitative or qualitative 
(descriptive) methods: 
Use quantitative methods, such as sensitivity analyses or meta-regression, when applicable in meta-analyses to investigate the 
impact of bias on meta-analysis effect estimates. In a systematic review without meta-analysis, visually present study findings 
according to risk of bias assessment findings or provide an informative discussion to speculate about influence of risk of bias 
on the credibility of research findings. 
7) Provide justification, based on the available risk of bias assessment criteria, to support each risk of bias judgement: 
Supplementary File 2 provides the final judgements allocated by assessors to each signalling question of RoB2 in our risk of 
bias re-assessment of eleven RCTs included in the systematic review by Kosik et al.(16) 
 
 
Summary 
Consistent, valid, and trustworthy assessments of risk of bias in RCTs are essential to judge the 
credibility of a body of evidence. Nearly all systematic reviews published in BJSM between January 
2016 and May 2017 included a critical assessment tool. However, few systematic reviews used 
domain-level risk of bias assessment tools or performed domain-level risk of bias assessments. 
Outcome types were rarely considered separately in risk of bias assessments.  Quantitative methods 
were infrequently used to incorporate risk of bias assessment findings into systematic review findings. 
We identified discrepancies between risk of bias and study quality assessment findings in our re-
assessment of a previous systematic review. Using different critical assessment tools generated 
different assessment findings, which affected inferences about the credibility of review findings. Risk 
of bias assessment tools must be correctly selected and administered, and findings interpreted and 
incorporated to inform the extent to which assessment findings likely impact a body of systematically-
reviewed evidence. 
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